| pubmed-article:1938514 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1938514 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:1938514 | lifeskim:mentions | umls-concept:C0043162 | lld:lifeskim |
| pubmed-article:1938514 | lifeskim:mentions | umls-concept:C0439682 | lld:lifeskim |
| pubmed-article:1938514 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
| pubmed-article:1938514 | lifeskim:mentions | umls-concept:C1156245 | lld:lifeskim |
| pubmed-article:1938514 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1938514 | pubmed:dateCreated | 1991-11-25 | lld:pubmed |
| pubmed-article:1938514 | pubmed:abstractText | The treatment of Non-Hodgkin's lymphomas with follicular growth pattern and advanced stage of disease remains controversial. Treatments varying from no initial treatment up to aggressive combination chemotherapy have been advocated. The EORTC Lymphoma Cooperative Group has performed a randomized prospective trial comparing short duration low dose total body irradiation (TBI) vs combination chemotherapy (CHVmP) + consolidation radiotherapy. Ninety-three patients were entered; of 84 evaluable patients, 44 received TBI and 40 CHVmP. Complete remission (CR) rates were 36%--TBI and 55%--CHVmP, but overall response rates were identical, 76 versus 69%. No significant difference in freedom from progression or survival was observed. No unexpected toxicity was seen. Although numbers are small, we cannot conclude that aggressive combination chemo-radiotherapy resulted in a better survival. Our analysis confirms that there is a constant risk of relapse. Other approaches should be explored if survival benefit is the ultimate goal in treatment of this patient population. | lld:pubmed |
| pubmed-article:1938514 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1938514 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1938514 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1938514 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1938514 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1938514 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1938514 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1938514 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1938514 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1938514 | pubmed:issn | 0360-3016 | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:ThomasJJ | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:SizooWW | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:SomersRR | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:MonconduitMM | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:BurgersJ MJM | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:MeerwaldtJ... | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:CardePP | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:DuezNN | lld:pubmed |
| pubmed-article:1938514 | pubmed:author | pubmed-author:GlabbekeM VMV | lld:pubmed |
| pubmed-article:1938514 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1938514 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:1938514 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1938514 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1938514 | pubmed:pagination | 1167-72 | lld:pubmed |
| pubmed-article:1938514 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:meshHeading | pubmed-meshheading:1938514-... | lld:pubmed |
| pubmed-article:1938514 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1938514 | pubmed:articleTitle | Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. | lld:pubmed |
| pubmed-article:1938514 | pubmed:affiliation | Medisch Spectrum Twente, Enschede, The Netherlands. | lld:pubmed |
| pubmed-article:1938514 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1938514 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1938514 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1938514 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
